Ritlecitinib, a JAK3/TEC inhibitor, shows therapeutic effects on alopecia areata by inhibiting IL-5 and IFN-γ (ritlecitinib may decrease the production of IFN-γ via an indirect mechanism, related to TEC kinase inhibition), which are also pathogenic cytokines in vitiligo and can therefore be used to treat this condition. This evidence concerns the gene IFNG and alopecia areata.